Radiopharmaceuticals are a type of pharmaceutical drug that has radioisotopes, which attach to biological molecules to target particular cells and tissues. It plays a crucial role in the field of precision medicine. There is a significant amount of research that is done in this field of medicine as it has the potential to offer radiotherapy with improved explicitness to cancer cells.
According to a report by Extrapolate, the global radiopharmaceuticals market size is anticipated to grow to around USD 8.8 billion by 2032, growing at a CAGR (compound annual growth rate) of around 7.4% between 2023 and 2032.
In this blog, let us have a look at the best companies that offer radiopharmaceuticals for therapy.
Top 10 Radiopharmaceuticals Companies
Here are the top companies that provide radiopharmaceuticals for health providers:
1. Bayer AG
Bayer AG is a global pharmaceutical leader in the development and commercialization of radiopharmaceuticals for therapy. The company combines its expertise in advanced imaging and targeted therapy to improve patient outcomes. It specifically focuses on oncology. Cancer patients can benefit from Bayer AG's portfolio in radiopharmaceuticals for therapy. These therapeutic radiopharmaceuticals have precise treatments that deliver therapeutic radiopharmaceuticals. It helps to reduce the damage to the surrounding healthy tissues. Xofigo (Radium-223 dichloride) is a revolutionary alpha-emitting radiopharmaceutical used in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who have symptomatic bone metastases. The company is actively developing PSMA-targeted radioligand therapies for prostate cancer.
2. Cardinal Health
Cardinal Health is a pioneer in the radiopharmaceutical industry. The company is well known for its comprehensive range of products and services. The company operates one of the biggest networks of nuclear pharmacies in the United States. It offers timely and reliable delivery of radiopharmaceuticals to healthcare providers. Prostate cancer, neuroendocrine tumors, and others are a range of cancers that Cardinal Health's therapeutic radiopharmaceuticals are designed to treat. Radioisotopes such as Iodine-131 and Lutetium-177 are advanced treatments used to emit radiation to destroy cancer cells. Cardinal Health plays a crucial role in advancing nuclear medicine and molecular imaging.
3. Eckert & Ziegler
Eckert & Ziegler is a key player in the radiopharmaceuticals sector that caters to a global market. It provides high-quality Yttrium-90 (Y-90) radiopharmaceuticals for selective internal radiation therapy (SIRT). Y-90 is a beta-emitting radionuclide used in the treatment of liver cancer and other malignancies.
Lu-177 is another key radionuclide offered by Eckert & Ziegler, which is used in targeted cancer therapies. Eckert & Ziegler is at the forefront of developing theranostics radiopharmaceuticals. The company is popular for combining therapeutic and diagnostic capabilities in a single agent.
Gallium-68 (Ga-68) and Lutetium-177 (Lu-177) theranostics are paired radionuclides used in a theranostic approach. Ga-68 is used for imaging and diagnosis, and Lu-177 is used for subsequent targeted therapy.
4. GE Healthcare
GE Healthcare specializes in providing a wide range of products and services designed to support diagnostic imaging and targeted therapy. The radiopharmaceuticals delivered by the company play a crucial role in the early detection and management of various diseases, such as cancer and neurological disorders. My view, Ceretec, and HMPAO are SPECT imaging agents used widely in diagnostic radiopharmaceuticals. Furthermore, DaTscan is a PET imaging agent used to diagnose movement diseases such as Parkinson's. Vizamyl is another PET imaging agent leveraged in the visualization of beta-amyloid neuritic plaque density in the brains of adult patients.
Lutetium Lu 177 and Iodine I 131 are therapeutic radiopharmaceuticals offered by GE Healthcare. The company invests heavily in R&D to advance the field of radiopharmaceuticals. Their radiopharmaceutical offerings are integral to modern medical imaging and targeted therapy.
5. Jubilant Pharma Limited
Jubilant Pharma Limited is a subsidiary of Jubilant Life Sciences. It is one of the major players in the radiopharmaceutical market. Fludeoxyglucose F 18 Injection (FDG), I-123 MIBG Injection, and Tc-99m Products are a few diagnostic radiopharmaceuticals provided by the company.
Jubilant Pharma offers contract manufacturing services for radiopharmaceuticals. The company invests in R&D to develop new radiopharmaceuticals and improve existing ones. Jubilant Pharma has a significant global presence, with operations in North America, Europe, and Asia.
6. NorthStar Medical Radioisotopes, LLC
NorthStar Medical Radioisotopes, LLC, primarily focuses on the production and supply of radioisotopes used in medical imaging and therapy. Molybdenum-99 (Mo-99), technetium-99m (Tc-99m) generators, and RadioGenix® System are a few of the products and services supplied by NorthStar. The company prioritizes safety and environmental sustainability. It has adopted production methods designed to minimize nuclear waste and reduce the environmental impact of radioisotope production.
NorthStar's innovative approach has helped them address critical supply chain challenges. The company ensures healthcare providers get easy access to essential diagnostic tools. NorthStar partners with various research institutions, healthcare providers, and industry partners to advance the field of nuclear medicine.
7. Novartis AG
Novartis AG is a global healthcare company that deals in the radiopharmaceuticals sector. Advanced Accelerator Applications (AAA) is a division of Novartis AG offering radiopharmaceutical products and services to its clients. Lutathera, also known as Lutetium Lu 177 dotatate, is a targeted radioligand therapy used for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). 177Lu-PSMA-617 is a radioligand therapy in clinical development for the treatment of prostate cancer. The company is conducting various clinical trials to evaluate the efficacy and safety of 177Lu-PSMA-617. Novartis adheres to strict regulatory and quality standards to ensure the safety, efficacy, and reliability of its radiopharmaceutical products.
8. NTP Radioisotopes SOC Ltd
NTP Radioisotopes SOC Ltd. is at the forefront of the global production and distribution of nuclear medicine products, radiochemicals, and industrial isotopes. NTP Radioisotopes is a subsidiary of the South African Nuclear Energy Corporation (NECSA). The company is based in South Africa.
Following are the products and services offered by NTP Radioisotopes SOC Ltd:
- Molybdenum-99 (Mo-99): Mo-99 is a critical isotope used to produce Technetium-99m (Tc-99m). It is the most widely used radioisotope in diagnostic imaging.
- Iodine-131 (I-131): I-131 is used for both diagnostic and therapeutic purposes, particularly in the treatment of thyroid disorders and certain types of cancer.
- Lutetium-177 (Lu-177): Lu-177 is a beta-emitting radioisotope used in targeted radionuclide therapy.
- Iridium-192 (Ir-192): Ir-192 is used in industrial radiography and brachytherapy.
- Fluorine-18 (F-18): F-18 is a positron-emitting isotope used in positron emission tomography (PET) imaging.
NTP Radioisotopes continues to make significant contributions to the advancement of nuclear medicine and the improvement of patient care globally.
9. Siemens Healthineers
Siemens Healthineers is a pioneer in the healthcare sector, offering a wide range of products and services in radiopharmaceuticals. Biograph™ PET/CT Systems, Symbia™ SPECT/CT Systems, and c.cam Cardiac SPECT are diagnostic radiopharmaceuticals offered by the company.
Siemens Healthineers offers solutions for quantitative PET imaging, which is crucial for theranostic radiopharmaceuticals applications. PETNET is a subsidiary of Siemens Healthineers. It is the largest PET radiopharmaceutical producer and distributor in the world.
10. Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited is a biopharmaceutical company with expertise in the development and commercialization of radiopharmaceuticals for diagnostic and therapeutic applications. Illuccix® (TLX591-CDx), TLX250-CDx, and TLX591-Sx are diagnostic radiopharmaceuticals supplied by Telix.
Telix provides the following therapeutic radiopharmaceuticals
- TLX591: A therapeutic radiopharmaceutical targeting PSMA for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
- TLX250: A therapeutic counterpart to TLX250-CDx. It uses the same targeting mechanism but with lutetium-177 (Lu-177) for the treatment of renal cancer.
- TLX101: It is designed for the treatment of glioblastoma. This product uses iodine-131 (I-131) labeled molecules to target LAT-1 (L-type amino acid transporter 1), which is overexpressed in glioblastoma cells.
Conclusion
There are various vendors in the radiopharmaceutical market that offer a wide range of products and services to diagnose and treat different medical conditions. The above-mentioned companies are the top 10 radiopharmaceuticals for therapy vendors that offer effective products to a global client base.
